These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31545001)

  • 1. A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer.
    Kind S; Jaretzke A; Büscheck F; Möller K; Dum D; Höflmayer D; Hinsch A; Weidemann S; Fraune C; Möller-Koop C; Hube-Magg C; Simon R; Wilczak W; Lebok P; Witzel I; Müller V; Schmalfeldt B; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Krech T; Krech RH; von der Assen A; Bawahab AA; Burandt E
    Mol Carcinog; 2019 Dec; 58(12):2306-2315. PubMed ID: 31545001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.
    Kind S; Kluth M; Hube-Magg C; Möller K; Makrypidi-Fraune G; Lutz F; Lennartz M; Rico SD; Schlomm T; Heinzer H; Höflmayer D; Weidemann S; Uhlig R; Huland H; Graefen M; Bernreuther C; Tsourlakis MC; Minner S; Dum D; Hinsch A; Lübke AM; Simon R; Sauter G; Marx A; Polonski A
    Biomed Res Int; 2020; 2020():5845374. PubMed ID: 33195694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors.
    Hashimoto Y; Skacel M; Adams JC
    BMC Cancer; 2008 Jun; 8():185. PubMed ID: 18590537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of syndecan-1 expression in ductal carcinoma in situ of the breast.
    Tiemann K; Weigel MT; Alkatout I; Wenners AS; Mundhenke H; Schäfer FW; Bauer M; Schem C; Maass N; Jonat W; Mundhenke C
    Anticancer Res; 2014 Jul; 34(7):3607-16. PubMed ID: 24982376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
    Schönfeld K; Herbener P; Zuber C; Häder T; Bernöster K; Uherek C; Schüttrumpf J
    Pharm Res; 2018 Apr; 35(6):118. PubMed ID: 29666962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.
    Ismail Y; Zakaria AS; Allam R; Götte M; Ibrahim SA; Hassan H
    Pathol Res Pract; 2024 Jan; 253():154994. PubMed ID: 38071886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer.
    Lebok P; Huber J; Burandt EC; Lebeau A; Marx AH; Terracciano L; Heilenkötter U; Jänicke F; Müller V; Paluchowski P; Geist S; Wilke C; Simon R; Sauter G; Quaas A
    Mol Med Rep; 2016 Aug; 14(2):1443-50. PubMed ID: 27357606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.
    Kind S; Merenkow C; Büscheck F; Möller K; Dum D; Chirico V; Luebke AM; Höflmayer D; Hinsch A; Jacobsen F; Göbel C; Weidemann S; Fraune C; Möller-Koop C; Hube-Magg C; Clauditz TS; Simon R; Sauter G; Wilczak W; Bawahab AA; Izbicki JR; Perez D; Marx A
    Dis Markers; 2019; 2019():4928315. PubMed ID: 31976021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
    Sharpe B; Alghezi DA; Cattermole C; Beresford M; Bowen R; Mitchard J; Chalmers AD
    Prostate; 2017 May; 77(13):1312-1324. PubMed ID: 28744948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases.
    Kambham N; Kong C; Longacre TA; Natkunam Y
    Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):304-10. PubMed ID: 16280658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic Trop-1/Ep-CAM overexpression is associated with a favorable outcome in node-positive breast cancer.
    Alberti S; Ambrogi F; Boracchi P; Fornili M; Querzoli P; Pedriali M; La Sorda R; Lattanzio R; Tripaldi R; Piantelli M; Biganzoli E; Coradini D
    Jpn J Clin Oncol; 2012 Dec; 42(12):1128-37. PubMed ID: 23072840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer.
    Bae YK; Kim A; Kim MK; Choi JE; Kang SH; Lee SJ
    Hum Pathol; 2013 Oct; 44(10):2028-37. PubMed ID: 23684510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of syndecan-1 expression in breast cancer.
    Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
    Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases.
    Kim SY; Choi EJ; Yun JA; Jung ES; Oh ST; Kim JG; Kang WK; Lee SH
    Int J Med Sci; 2015; 12(2):92-9. PubMed ID: 25589885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
    Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
    Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
    Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.
    Mirza S; Rakha EA; Alshareeda A; Mohibi S; Zhao X; Katafiasz BJ; Wang J; Gurumurthy CB; Bele A; Ellis IO; Green AR; Band H; Band V
    Breast Cancer Res Treat; 2013 Feb; 137(3):721-31. PubMed ID: 23288344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.
    Têtu B; Brisson J
    Cancer; 1994 May; 73(9):2359-65. PubMed ID: 7909490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody.
    Keshgegian AA; Cnaan A
    Am J Clin Pathol; 1997 Oct; 108(4):456-63. PubMed ID: 9322600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.